Work

ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps8052

Authors: Michael A. Thompson, Susanna J. Jacobus, Shaji Kumar, Murali Janakiram, Sagar Lonial, Matthias Weiss, Natalie Scott Callander, S. Vincent Rajkumar

Institutions: Aurora Health Care, Dana-Farber Cancer Institute, Mayo Clinic, University of Minnesota, Winship Cancer Institute, ThedaCare, University of Wisconsin System

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954488068

Cites:

Cited by: 3

Related to: 10